{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T10:38:01Z","timestamp":1789987081364,"version":"4.0.1"},"reference-count":43,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T00:00:00Z","timestamp":1613520000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>The gastrointestinal tract (GIT) can be broadly divided into several regions: the stomach, the small intestine (which is subdivided to duodenum, jejunum, and ileum), and the colon. The conditions and environment in each of these segments, and even within the segment, are dependent on many factors, e.g., the surrounding pH, fluid composition, transporters expression, metabolic enzymes activity, tight junction resistance, different morphology along the GIT, variable intestinal mucosal cell differentiation, changes in drug concentration (in cases of carrier-mediated transport), thickness and types of mucus, and resident microflora. Each of these variables, alone or in combination with others, can fundamentally alter the solubility\/dissolution, the intestinal permeability, and the overall absorption of various drugs. This is the underlying mechanistic basis of regional-dependent intestinal drug absorption, which has led to many attempts to deliver drugs to specific regions throughout the GIT, aiming to optimize drug absorption, bioavailability, pharmacokinetics, and\/or pharmacodynamics. In this Editorial we provide an overview of the Special Issue \"Regional Intestinal Drug Absorption: Biopharmaceutics and Drug Formulation\". The objective of this Special Issue is to highlight the current progress and to provide an overview of the latest developments in the field of regional-dependent intestinal drug absorption and delivery, as well as pointing out the unmet needs of the field.<\/jats:p>","DOI":"10.3390\/pharmaceutics13020272","type":"journal-article","created":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T21:35:42Z","timestamp":1613597742000},"page":"272","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Regional Intestinal Drug Absorption: Biopharmaceutics and Drug Formulation"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3498-3514","authenticated-orcid":false,"given":"Arik","family":"Dahan","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacology, School of Pharmacy, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 8410501, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1685-142X","authenticated-orcid":false,"given":"Isabel","family":"Gonz\u00e1lez-\u00c1lvarez","sequence":"additional","affiliation":[{"name":"Engineering, Pharmacokinetics and Pharmaceutical Technology Area, Miguel Hernandez University, 03550 Juan de Alicante, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,2,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1021\/mp100175a","article-title":"High-Permeability Criterion for BCS Classification: Segmental\/pH Dependent Permeability Considerations","volume":"7","author":"Dahan","year":"2010","journal-title":"Mol. Pharm."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1208\/s12248-013-9462-x","article-title":"Regional-Dependent Intestinal Permeability and BCS Classification: Elucidation of pH-Related Complexity in Rats Using Pseudoephedrine","volume":"15","author":"Fairstein","year":"2013","journal-title":"AAPS J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ejpb.2016.02.002","article-title":"Effects of gastric pH on oral drug absorption: In vitro assessment using a dissolution\/permeation system reflecting the gastric dissolution process","volume":"101","author":"Kataoka","year":"2016","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.ijpharm.2015.05.002","article-title":"The biopharmaceutics of successful controlled release drug product: Segmental-dependent permeability of glipizide vs. metoprolol throughout the intestinal tract","volume":"489","author":"Zur","year":"2015","journal-title":"Int. J. Pharm."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1021\/mp500152y","article-title":"The Low\/High BCS Permeability Class Boundary: Physicochemical Comparison of Metoprolol and Labetalol","volume":"11","author":"Zur","year":"2014","journal-title":"Mol. Pharm."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ejps.2013.11.007","article-title":"The complexity of intestinal permeability: Assigning the correct BCS classification through careful data interpretation","volume":"61","author":"Zur","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Figueroa-Campos, A., S\u00e1nchez-Dengra, B., Merino, V., Dahan, A., Gonz\u00e1lez-\u00c1lvarez, I., Garc\u00eda-Arieta, A., Gonz\u00e1lez-\u00c1lvarez, M., and Bermejo, M. (2020). Candesartan Cilexetil In Vitro\u2013In Vivo Correlation: Predictive Dissolution as a Development Tool. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12070633"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.ejps.2013.09.008","article-title":"PBPK models for the prediction of in vivo performance of oral dosage forms","volume":"57","author":"Kostewicz","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1021\/mp100149j","article-title":"Physiological Parameters for Oral Delivery and in Vitro Testing","volume":"7","author":"Mudie","year":"2010","journal-title":"Mol. Pharm."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1021\/mp800088f","article-title":"Segmental Dependent Transport of Low Permeability Compounds along the Small Intestine Due to P-Glycoprotein: The Role of Efflux Transport in the Oral Absorption of BCS Class III Drugs","volume":"6","author":"Dahan","year":"2009","journal-title":"Mol. Pharm."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1124\/dmd.109.028282","article-title":"Multiple Efflux Pumps Are Involved in the Transepithelial Transport of Colchicine: Combined Effect of P-Glycoprotein and Multidrug Resistance-Associated Protein 2 Leads to Decreased Intestinal Absorption Throughout the Entire Small Intestine","volume":"37","author":"Dahan","year":"2009","journal-title":"Drug Metab. Dispos."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1124\/dmd.110.034025","article-title":"Significance and Regional Dependency of Peptide Transporter (PEPT) 1 in the Intestinal Permeability of Glycylsarcosine: In Situ Single-Pass Perfusion Studies in Wild-Type and Pept1 Knockout Mice","volume":"38","author":"Jappar","year":"2010","journal-title":"Drug Metab. Dispos."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1007\/s11095-007-9519-6","article-title":"Pharmacokinetics of the CYP 3A Substrate Simvastatin following Administration of Delayed Versus Immediate Release Oral Dosage Forms","volume":"25","author":"Hilfinger","year":"2008","journal-title":"Pharm. Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1124\/dmd.116.072231","article-title":"Regional Expression Levels of Drug Transporters and Metabolizing Enzymes along the Pig and Human Intestinal Tract and Comparison with Caco-2 Cells","volume":"45","author":"Vaessen","year":"2017","journal-title":"Drug Metab. Dispos."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.vetmic.2015.03.022","article-title":"Structural alteration of tight and adherens junctions in villous and crypt epithelium of the small and large intestine of conventional nursing piglets infected with porcine epidemic diarrhea virus","volume":"177","author":"Jung","year":"2015","journal-title":"Vet. Microbiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1021\/mp500553b","article-title":"Intestinal Permeability Study of Minoxidil: Assessment of Minoxidil as a High Permeability Reference Drug for Biopharmaceutics Classification","volume":"12","author":"Ozawa","year":"2015","journal-title":"Mol. Pharm."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1021\/mp300140h","article-title":"The Fraction Dose Absorbed, in Humans, and High Jejunal Human Permeability Relationship","volume":"9","author":"Dahan","year":"2012","journal-title":"Mol. Pharm."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.ejps.2013.08.025","article-title":"Regional intestinal drug permeation: Biopharmaceutics and drug development","volume":"57","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1021\/mp4003392","article-title":"Human in Vivo Regional Intestinal Permeability: Importance for Pharmaceutical Drug Development","volume":"11","year":"2014","journal-title":"Mol. Pharm."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1208\/s12248-015-9758-0","article-title":"Translating Human Effective Jejunal Intestinal Permeability to Surface-Dependent Intrinsic Permeability: A Pragmatic Method for a More Mechanistic Prediction of Regional Oral Drug Absorption","volume":"17","author":"Aarons","year":"2015","journal-title":"AAPS J."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"105440","DOI":"10.1016\/j.ejps.2020.105440","article-title":"Biopharmaceutical characterization of rebamipide: The role of mucus binding in regional-dependent intestinal permeability","volume":"152","author":"Markovic","year":"2020","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1124\/dmd.118.083402","article-title":"How to Determine the Role of the Microbiome in Drug Disposition","volume":"46","author":"Bisanz","year":"2018","journal-title":"Drug Metab. Dispos."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1124\/pr.118.015768","article-title":"Gut Reactions: Breaking Down Xenobiotic\u2013Microbiome Interactions","volume":"71","author":"Clarke","year":"2019","journal-title":"Pharmacol. Rev."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrmicro.2016.17","article-title":"The microbial pharmacists within us: A metagenomic view of xenobiotic metabolism","volume":"14","author":"Spanogiannopoulos","year":"2016","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.addr.2016.04.018","article-title":"The solubility\u2013permeability interplay and oral drug formulation design: Two heads are better than one","volume":"101","author":"Dahan","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Fine-Shamir, N., Beig, A., and Dahan, A. (2021). Adequate Formulation Approach for Oral Chemotherapy: Etoposide Solubility, Permeability, and Overall Bioavailability from Cosolvent- vs. Vitamin E TPGS-Based Delivery Systems. Int. J. Pharm.","DOI":"10.1016\/j.ijpharm.2021.120295"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Lozoya-Agullo, I., Zur, M., Beig, A., Fine, N., Cohen, Y., Gonz\u00e1lez-\u00c1lvarez, M., Merino-Sanju\u00e1n, M., Gonz\u00e1lez-\u00c1lvarez, I., Bermejo, M., and Dahan, A. (2016). Segmental-dependent permeability throughout the small intestine following oral drug administration: Single-pass vs. Doluisio approach to in-situ rat perfusion. Int. J. Pharm., 201\u2013208.","DOI":"10.1016\/j.ijpharm.2016.09.061"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.xphs.2018.07.017","article-title":"Segmental-Dependent Intestinal Drug Permeability: Development and Model Validation of In Silico Predictions Guided by In Vivo Permeability Values","volume":"108","author":"Wolk","year":"2019","journal-title":"J. Pharm. Sci."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Teixeira, L.d., Chagas, T.V., Alonso, A., Gonzalez-Alvarez, I., Bermejo, M., Polli, J., and Rezende, K.R. (2020). Biomimetic Artificial Membrane Permeability Assay over Franz Cell Apparatus Using BCS Model Drugs. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12100988"},{"key":"ref_30","first-page":"2","article-title":"Closed-Loop Doluisio (Colon, Small Intestine) and Single-Pass Intestinal Perfusion (Colon, Jejunum) in Rat\u2014Biophysical Model and Predictions Based on Caco-2","volume":"35","author":"Zur","year":"2017","journal-title":"Pharm. Res."},{"key":"ref_31","first-page":"2209","article-title":"In Silico Assessment of ADME Properties: Advances in Caco-2 Cell Monolayer Permeability Modeling","volume":"18","author":"Nam","year":"2018","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1021\/mp4000585","article-title":"Provisional Classification and in Silico Study of Biopharmaceutical System Based on Caco-2 Cell Permeability and Dose Number","volume":"10","author":"Garrigues","year":"2013","journal-title":"Mol. Pharm."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Ta, G.H., Jhang, C.-S., Weng, C.-F., and Leong, M.K. (2021). Development of a Hierarchical Support Vector Regression-Based In Silico Model for Caco-2 Permeability. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13020174"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Ruiz-Picazo, A., Col\u00f3n-Useche, S., Perez-Amor\u00f3s, B., Gonz\u00e1lez-\u00c1lvarez, M., Molina-Mart\u00ednez, I., Gonz\u00e1lez-\u00c1lvarez, I., Garc\u00eda-Arieta, A., and Bermejo, M. (2019). Investigation to Explain Bioequivalence Failure in Pravastatin Immediate-Release Products. Pharmaceutics, 11.","DOI":"10.3390\/pharmaceutics11120663"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Bermejo, M., Hens, B., Dickens, J., Mudie, D., Paix\u00e3o, P., Tsume, Y., Shedden, K., and Amidon, G.L. (2020). A Mechanistic Physiologically-Based Biopharmaceutics Modeling (PBBM) Approach to Assess the In Vivo Performance of an Orally Administered Drug Product: From IVIVC to IVIVP. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12010074"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Markovic, M., Zur, M., Ragatsky, I., Cviji\u0107, S., and Dahan, A. (2020). BCS Class IV Oral Drugs and Absorption Windows: Regional-Dependent Intestinal Permeability of Furosemide. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12121175"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Ruiz-Garcia, A., Tan, W., Li, J., Haughey, M., Masters, J., Hibma, J., and Lin, S. (2020). Pharmacokinetic Models to Characterize the Absorption Phase and the Influence of a Proton Pump Inhibitor on the Overall Exposure of Dacomitinib. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12040330"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Dahlgren, D., Cano-Cebri\u00e1n, M.-J., Olander, T., Hedeland, M., Sj\u00f6blom, M., and Lennern\u00e4s, H. (2020). Regional Intestinal Drug Permeability and Effects of Permeation Enhancers in Rat. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12030242"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Fu, M., Al-Gousous, J., Blechar, J.A., and Langguth, P. (2020). Enteric Hard Capsules for Targeting the Small Intestine: Positive Correlation between In Vitro Disintegration and Dissolution Times. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12020123"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Markovic, M., Zur, M., Fine-Shamir, N., Haimov, E., Gonz\u00e1lez-\u00c1lvarez, I., and Dahan, A. (2020). Segmental-Dependent Solubility and Permeability as Key Factors Guiding Controlled Release Drug Product Development. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12030295"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Christfort, J.F., Guillot, A.J., Melero, A., Thamdrup, L.H.E., Garrigues, T.M., Boisen, A., Z\u00f3r, K., and Nielsen, L.H. (2020). Cubic Microcontainers Improve In Situ Colonic Mucoadhesion and Absorption of Amoxicillin in Rats. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12040355"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Pang, K.S., Peng, H.B., and Noh, K. (2020). The Segregated Intestinal Flow Model (SFM) for Drug Absorption and Drug Metabolism: Implications on Intestinal and Liver Metabolism and Drug\u2013Drug Interactions. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12040312"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Xie, C., Jones, K.L., Rayner, C.K., and Wu, T. (2020). Enteroendocrine Hormone Secretion and Metabolic Control: Importance of the Region of the Gut Stimulation. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12090790"}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/13\/2\/272\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:25:23Z","timestamp":1760160323000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/13\/2\/272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,17]]},"references-count":43,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2]]}},"alternative-id":["pharmaceutics13020272"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics13020272","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,17]]}}}